• Lunai Bioworks posted a net loss of USD 2.57 million for quarter ended March 31, 2026, swinging from net income of USD 189,176 a year earlier as operating loss narrowed 66% to USD 1.43 million.
• Revenue was USD 20,942, compared with no revenue a year earlier, while operating expenses fell 65% to USD 1.45 million on a 66% drop in general and administrative costs to USD 1.42 million.
• Cash and cash equivalents totaled USD 3.16 million at March 31, 2026, up from USD 92,700 at June 30, 2025, while working capital deficit narrowed 45% to USD 15.55 million.
• Operations were focused on Renovaro Biosciences cell and gene therapy programs and BioSymetrics AI platform following GediCube’s bankruptcy and deconsolidation, with management aiming to fund operations through additional equity or debt financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000749), on May 15, 2026, and is solely responsible for the information contained therein.